Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 217

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Triple negative breast cancer+1

Not recruiting

Study of MEN1611 and Eribulin for Advanced Metaplastic Breast Cancer in Patients with PIK3CA/PTEN Alterations

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Eribulin
  • Sponsor:Medica Scientia Innovation Research S.L.

Plasma cell myeloma

Not recruiting

Study on the Effects of Isatuximab with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Acasunlimab and Pembrolizumab for Patients with Recurrent Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acasunlimab
  • Sponsor:Genmab A/S

Endometrial sarcoma

Not recruiting

Study on Stopping or Continuing Anastrozole, Letrozole, and Exemestane for Patients with Advanced or Metastatic Low-Grade Endometrial Stromal Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:Centre Leon Berard

Cholangiocarcinoma+3

Not recruiting

Study of Durvalumab, Tremelimumab, and Capecitabine for Patients with Biliary Tract Cancer in an Adjuvant Setting

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Plasma cell myeloma refractory

Not recruiting

Study of belantamab mafodotin, bortezomib and dexamethasone combination in adults with relapsed or refractory multiple myeloma who received at least one prior therapy

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Ceska Myelomova Skupina z.s.

Prostate cancer

Not recruiting

Study of Apalutamide for Patients with High-Risk Prostate Cancer After Prostate Removal

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Universitaet Muenster

Plasma cell myeloma

Not recruiting

Study on [68Ga]Ga-PentixaFor for Staging and Evaluation in Symptomatic Multiple Myeloma Patients in Initial Treatment or Relapse

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pentixafor gallium GA-68
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Chronic myeloid leukaemia

Not recruiting

Study on the Effectiveness of Asciminib and Imatinib for Patients with Chronic Myelogenous Leukemia Not Responding to Imatinib

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Novartis Pharma AG

Transitional cell carcinoma

Not recruiting

Study of Atezolizumab Treatment Before Surgery in Patients with Bladder Cancer or Upper Urinary Tract Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Queen Mary University Of London

Chronic lymphocytic leukaemia+2

Not recruiting

Study on the Effects of Acalabrutinib in Patients with Chronic Lymphocytic Leukemia, Richter's Syndrome, or Prolymphocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Small cell lung cancer+1

Not recruiting

Study of Atezolizumab, Carboplatin, and Etoposide with or Without Tiragolumab for Patients with Untreated Extensive-Stage Small Cell Lung Cancer

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.